EUCTR2008-000709-12-AT进行中（未招募）不适用
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast Cancer
Teva Branded Pharmeceutical Products R&D, Inc.0 个研究点目标入组 120 人开始时间: 2008年5月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients are included in the study if all of the following criteria are met:
- •(a) Treatment-naïve patients have stage II or III invasive breast cancer histologically/cytologically proven and overexpressing human epidermal growth factor reeptor 2 (HER2) as demonstrated by fluorescence in situ hybridization (FISH) highly preferable or by SISH or by CISH.
- •(b) Patients have at least 1 bidimensionally measurable lesion according to the WHO criteria.
- •(c) The patient is a woman 18 to 70 years of age, inclusive.
- •(d) Written informed consent is obtained.
- •(e) The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •(f) The patient has an LVEF of at least 55% as assessed by multiple-gated acquisition (MUGA) scan (preferred) or echocardiography.
- •(g) The patient has haematology and serum chemistry laboratory test results within the following ranges:
- •at least 2x10^9 neutrophils/L
- •at least 100x10^9 platelets/L
- •total bilirubin serum concentrations not exceeding the normal laboratory reference range
- •aspartate aminotransferase (AST) serum levels not exceeding 2.5 times the upper limit of normal (ULN)
- •alanine aminotransferase (ALT) serum levels not exceeding 2.5xULN
- •alkaline phosphatase (ALP) serum levels not exceeding 5.0xULN
- •serum creatinine serum levels not exceeding 1.5xULN
- •(h) Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the treatment period and for 6 months after the last administration of study drug. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device, or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
- •(i) The patient must be willing and able to comply with study assessments and willing to return to the clinic for further treatment and follow-up as specified in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- •(a) The patient has received previous cancer therapy for breast cancer.
- •(b) The patient has any history of coronary heart failure (CHF), angina pectoris, or myocardial infarction.
- •(c) The patient has uncontrolled hypertension.
- •(d) The patient has infection, peptic ulcer, or unstable diabetes mellitus.
- •(e) The patient has been treated with live virus vaccines within 8 weeks before the first administration of study drug.
- •(f) The patient has impaired hepatic or renal function.
- •(g) The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
- •(h) The patient has used an investigational drug within 1 month before the screening visit.
- •(i) The patient has a known hypersensitivity to any of the study drugs or to their active ingredients.
- •(j) The patient has an inflammatory breast cancer.
- •(k) The patient has any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
研究者
相似试验
进行中（未招募）
1 期
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast CancerPatients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-000709-12-FRCephalon France120
进行中（未招募）
不适用
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast CancerEUCTR2008-000709-12-NLCephalon France120
进行中（未招募）
不适用
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment Naïve Patients With HER2 Positive Breast Cancer - NDEUCTR2008-000709-12-ITCEPHALON FRANCE120
进行中（未招募）
不适用
Study of combination therapy of MYOCET® plus cyclophosphamide and trastuzumab versus free doxorubicin plus cyclophosphamide alone, each followed by docetaxel and trastuzumab, in patients with HER2-positive breast cancer who have not previously been treated with this drug combination.Patients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancerMedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864EUCTR2008-000709-12-BETeva Branded Pharmaceutical Products R&D, Inc.120
进行中（未招募）
不适用
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naïve Patients With HER2-Positive Breast CancerPatients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-000709-12-GBCephalon France120